Inactive Instrument

Amarillo Biosciences, Inc. Stock Other OTC

Equities

AMAR

US02301P2056

Biotechnology & Medical Research

Sales 2022 3.52M Sales 2023 122K Capitalization 8.32M
Net income 2022 -14M Net income 2023 -13M EV / Sales 2022 3.36 x
Net cash position 2022 585K Net Debt 2023 3.81M EV / Sales 2023 99.3 x
P/E ratio 2022
-0.6 x
P/E ratio 2023
-0.61 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 39.12%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 54 21-04-14
Chief Operating Officer 55 21-07-31
Sales & Marketing - -
Members of the board TitleAgeSince
Director/Board Member 70 21-04-14
Director/Board Member 66 22-06-14
Director/Board Member 47 21-04-14
More insiders
Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.
More about the company